WHO Updates for Myelodysplastic Syndrome and Myeloproliferative Neoplasms
This presentation will cover WHO updates for both myelodysplastic syndromes and myeloproliferative neoplasms. For myelodysplastic syndromes, emphasis will be placed on the role of somatic gene mutation testing in the diagnosis and prognostication. The challenge of distinction of myelodyspslastic syndromes from preclinical states characterized by clonal hematopoiesis will be discussed. As for updates related to myeloproliferative neoplasms (MPNs), categories have not changed significantly except the exclusion of mastocytosis. Mastocytosis is now a separate category due to its unique clinical and pathologic features. The update will focus on the molecular as well as the clinical and pathological changes that have been incorporated into the current diagnostic categories of MPNs.
